XLK provides concentrated exposure to the S&P 500 technology sector through ~77 holdings, with NVDA , AAPL , and MSFT accounting for roughly one-third of the portfolio. The ETF has been roughly flat over the past 30 days, but that headline masks a sharp mid-July correction of approximately 10% followed by an equally forceful rebound.

XLE is a passively managed ETF tracking the Energy Select Sector Index, holding approximately 24 S&P 500 energy stocks with a concentrated portfolio where the top three names — XOM , CVX , and COP — account for nearly half of net assets. The energy sector has been the top-performing S&P 500 sector in 2026, buoyed by the Iran conflict, restricted Strait of Hormuz transit, and WTI crude prices that more than doubled from their late-2025 lows before settling in the $75–$85 range.

SOXX declined -1.15% during Monday's regular trading session, reversing from pre-market gains where chip stocks initially traded broadly higher. Memory chip names sold off after reports emerged that Apple is testing China's CXMT memory chips for potential use in iPhones and MacBooks, threatening incumbent suppliers like Micron.

SOXL currently trades near $140, meaning a move to $200 would require roughly a 43% gain from recent levels. The fund's 52-week range spans from $23.66 to $302.00, illustrating both the extraordinary upside potential and severe downside risk embedded in a 3x daily leveraged product.

NWBO shares declined approximately 12.5% over the 30-day period ending early August 2026, falling from around $0.18 to roughly $0.16. The stock touched a 52-week low of $0.1411 on July 16, marking the lowest point in more than a year for the clinical-stage biotech.

IBM shares are trading at $238.99 during Monday's regular session, up +0.72% from Friday's close of $237.28, extending the stock's V-shaped recovery from its historic July collapse. The stock advanced despite trading ex-dividend today for a $1.69 quarterly payout, which normally exerts downward pressure — underscoring the strength of the current rebound bid.

Biogen (BIIB) delivered stronger recent performance with a significant Q2 2026 earnings beat and raised full-year guidance, while Pfizer (PFE) trades near 52-week lows ahead of its upcoming earnings. BIIB has posted robust year-to-date and one-year returns compared to PFE’s more modest gains, reflecting differing momentum in the biotechnology and pharmaceutical sectors.

AMGN trades near $385 with upcoming Q2 2026 earnings expected on August 4, following Q1 revenue growth of 6% to $8.6 billion and consistent earnings beats. BIIB closed recently around $203 after reporting Q2 revenue of $2.74 billion (up 3.4% year-over-year) and non-GAAP EPS well above estimates, with mixed stock reactions including gains of nearly 6% on one session.

AMGN and LLY both operate in the biopharmaceutical sector but differ markedly in scale and growth trajectories, with LLY demonstrating significantly higher recent revenue expansion driven by its GLP-1 portfolio. Recent market activity shows AMGN delivering steady single-digit revenue growth and maintaining consistent dividend payouts, while LLY reported 56% year-over-year revenue increase in the first quarter of 2026 alongside upward guidance revisions.

Both ETFs provide direct physical gold exposure by holding allocated gold bullion, tracking the LBMA Gold Price PM with minimal tracking error over time. Goldman Sachs Physical Gold ETF (AAAU) offers a significantly lower expense ratio of 0.18% compared to SPDR Gold Shares (GLD) at 0.40%, providing a structural cost advantage for long-term holders.

LRCX delivered approximately 82% year-to-date returns through early August 2026, significantly outpacing NVDA ’s roughly 20% gain over the same period. LRCX reported record quarterly revenue of $6.72 billion for the period ended June 28, 2026, with 30% year-over-year growth and gross margins reaching 52%.

MP is a leading U.S. rare earth producer with integrated mining and magnet manufacturing, benefiting from government price support and defense initiatives. UAMY focuses on antimony and related critical minerals, recently securing a major $245 million U.S. Defense Logistics Agency contract that has driven sharp revenue growth.

Both MP and USAR operate in the rare earth materials sector, positioning them as key players in U.S. efforts to reduce reliance on foreign supply chains for critical minerals used in electric vehicles, renewables, and defense applications. MP benefits from established production at its Mountain Pass facility, while USAR focuses on vertical integration including mining, processing, and magnet manufacturing with recent expansion moves.

COHR dropped -9.04% during Monday's regular trading session, surrendering a large portion of last week's explosive gains. The selloff is primarily profit-taking after the stock surged over +31% in the prior week, driven by FCC proposals to restrict Chinese optical transceiver imports and a $2 billion NVIDIA strategic partnership.

USA Rare Earth (USAR) shares edged approximately 3.9% higher over the last 30 days, trading near $19.20, reflecting a modest recovery from July lows. The company is aggressively executing a mine-to-magnet vertical integration strategy, anchored by its Stillwater, Oklahoma magnet manufacturing facility and multiple high-profile acquisitions.

TENX crashed -88.10% from its previous close of $13.44 to ~$1.60, with the collapse beginning in premarket trading and extending into the regular session. The primary catalyst: Tenax announced its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) for PH-HFpEF failed to meet both its primary endpoint on 6-minute walk distance and its key secondary endpoint on symptom improvement.

LINC plunged -21.54% during Monday's regular session after reporting Q2 CY2026 earnings before the open, despite beating consensus on revenue ($142.6M vs. $138.9M) and EPS ($0.06 vs. -$0.01 expected). The primary selloff catalyst was student starts growing only +1% year-over-year, a dramatic deceleration from Q1's +19.5%, as fewer enrolled students attended first-day classes amid shifting decision-making patterns.

NABL plunged -35.27% to $3.23 during regular trading on Monday after reporting Q2 2026 results before the open, gapping down sharply from its Aug 7 close of $4.99. Q2 EPS of $0.10 matched consensus, but revenue of $138.2M narrowly missed the $138.38M estimate, while subscription revenue rose +6.1% year-over-year to $137.1M.

AEVA shares tumbled -11.65% during Monday's regular session, retreating to ~$23.52 from Friday's close of $26.62 as a sharp post-earnings profit-taking wave accelerated. The decline follows an explosive +51% rally over the prior week, triggered by better-than-feared Q2 results and the launch of an Optical Connectivity business targeting AI data center hyperscalers.

USAR is trading at $19.50 during Monday's regular session, up +0.88% from Friday's close of $19.33, adding to last week's +29% surge from $14.95. The primary catalyst is anticipation ahead of the company's Q2 2026 earnings release after today's market close, with analysts forecasting an EPS loss of -$0.19 on revenue of $6.45 million.